{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:45:34Z","timestamp":1790113534078,"version":"4.0.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,28]]},"DOI":"10.7759\/cureus.97999","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:28:43Z","timestamp":1764325723000},"source":"Crossref","is-referenced-by-count":2,"title":["The Immunoglobulin A Nephropathy Renaissance: From Pathogenesis to Personalized Therapy"],"prefix":"10.7759","author":[{"given":"Samyuktha","family":"Srinivas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Kumar","family":"Madhavaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A","family":"Bhanushali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartik","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1436923","article-title":"Contemporary review of IgA nephropathy","volume":"15","author":"Filippone EJ","year":"2024","unstructured":"Filippone EJ, Gulati R, Farber JL. Contemporary review of IgA nephropathy. Front Immunol. 2024, 15:1436923. 10.3389\/fimmu.2024.1436923","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s40557-016-0118-z","article-title":"IgA nephropathy in a laboratory worker that progressed to end-stage renal disease: a case report","volume":"28","author":"Min B","year":"2016","unstructured":"Min B, Kim G, Kang T, Yoon C, Cho SI, Paek D. IgA nephropathy in a laboratory worker that progressed to end-stage renal disease: a case report. Ann Occup Environ Med. 2016, 28:35. 10.1186\/s40557-016-0118-z","journal-title":"Ann Occup Environ Med"},{"key":"ref3","unstructured":"KDIGO 2024 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV). public review draft. (2024). Accessed: November 8, 2025: https:\/\/kdigo.org\/wp-content\/uploads\/2024\/08\/KDIGO-2024-IgAN-IgAV-Guideline-Public-Review-Draft.pdf."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2004.01.001","article-title":"Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome","volume":"24","author":"D'Amico G","year":"2004","unstructured":"D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol. 2004, 24:179-96. 10.1016\/j.semnephrol.2004.01.001","journal-title":"Semin Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13020303","article-title":"IgA nephropathy: current understanding and perspectives on pathogenesis and targeted treatment","volume":"13","author":"Du Y","year":"2023","unstructured":"Du Y, Cheng T, Liu C, et al.. IgA nephropathy: current understanding and perspectives on pathogenesis and targeted treatment. Diagnostics (Basel). 2023, 13:303. 10.3390\/diagnostics13020303","journal-title":"Diagnostics (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-024-03555-5","article-title":"Review on epidemiology, disease burden, and treatment patterns of IgA nephropathy in select APAC countries","volume":"25","author":"Zaidi O","year":"2024","unstructured":"Zaidi O, Du F, Tang Z, Bhattacharjee S, Pareja K. Review on epidemiology, disease burden, and treatment patterns of IgA nephropathy in select APAC countries. BMC Nephrol. 2024, 25:136. 10.1186\/s12882-024-03555-5","journal-title":"BMC Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000000000165","article-title":"Global incidence of IgA nephropathy by race and ethnicity: a systematic review","volume":"4","author":"Kiryluk K","year":"2023","unstructured":"Kiryluk K, Freedberg DE, Radhakrishnan J, et al.. Global incidence of IgA nephropathy by race and ethnicity: a systematic review. Kidney360. 2023, 4:1112-22. 10.34067\/KID.0000000000000165","journal-title":"Kidney360"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.23876\/j.krcp.23.127","article-title":"School urinary screening program in Japan: history, outcomes, perspectives","volume":"43","author":"Honda M","year":"2024","unstructured":"Honda M, Yanagihara T, Gotoh Y. School urinary screening program in Japan: history, outcomes, perspectives. Kidney Res Clin Pract. 2024, 43:287-98. 10.23876\/j.krcp.23.127","journal-title":"Kidney Res Clin Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad199","article-title":"Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis","volume":"16","author":"Lee M","year":"2023","unstructured":"Lee M, Suzuki H, Nihei Y, Matsuzaki K, Suzuki Y. Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis. Clin Kidney J. 2023, 16:ii1-8. 10.1093\/ckj\/sfad199","journal-title":"Clin Kidney J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.16","article-title":"Aberrant glycosylation of IgA1 IS inherited in both pediatric IGA nephropathy and Henoch-Sch\u00f6nlein purpura nephritis","volume":"80","author":"Kiryluk K","year":"2011","unstructured":"Kiryluk K, Moldoveanu Z, Sanders JT, et al.. Aberrant glycosylation of IgA1 IS inherited in both pediatric IGA nephropathy and Henoch-Sch\u00f6nlein purpura nephritis. Kidney Int. 2011, 80:79-87. 10.1038\/ki.2011.16","journal-title":"Kidney Int"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-017-3699-z","article-title":"New insights into the pathogenesis of IgA nephropathy","volume":"33","author":"Yeo SC","year":"2018","unstructured":"Yeo SC, Cheung CK, Barratt J. New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol. 2018, 33:763-77. 10.1007\/s00467-017-3699-z","journal-title":"Pediatr Nephrol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefroe.2023.02.010","article-title":"IgA nephropathy after long-term treatment with infliximab for Crohn's disease Crohn's disease, a review of two cases","volume":"44","author":"Montero SS","year":"2024","unstructured":"Montero SS, Guix EM, Aus\u00edn MS, et al.. IgA nephropathy after long-term treatment with infliximab for Crohn's disease Crohn's disease, a review of two cases. Nefrologia (Engl Ed). 2024, 44:599-601. 10.1016\/j.nefroe.2023.02.010","journal-title":"Nefrologia (Engl Ed)"},{"key":"ref13","unstructured":"From lupus to celiac. conditions associated with IgA nephropathy. (2025). Accessed: November 8, 2025: https:\/\/www.healthline.com\/health\/kidney-disease\/conditions-associated-with-iga-nephropathy."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5114\/ceji.2019.84021","article-title":"IgA nephropathy associated with coeliac disease","volume":"44","author":"Habura I","year":"2019","unstructured":"Habura I, Fiedorowicz K, Wo\u017aniak A, Idasiak-Piechocka I, Kosikowski P, Oko A. IgA nephropathy associated with coeliac disease. Cent Eur J Immunol. 2019, 44:106-8. 10.5114\/ceji.2019.84021","journal-title":"Cent Eur J Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12072726","article-title":"Secondary IgA nephropathy and IgA-associated nephropathy: a systematic review of case reports","volume":"12","author":"Tota M","year":"2023","unstructured":"Tota M, Baron V, Musial K, et al.. Secondary IgA nephropathy and IgA-associated nephropathy: a systematic review of case reports. J Clin Med. 2023, 12:2726. 10.3390\/jcm12072726","journal-title":"J Clin Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1175477","article-title":"Association of psoriasis with chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis","volume":"10","author":"Jing X","year":"2023","unstructured":"Jing X, Zhuyuan W, Aijun C, Jianxia X, Kun H, Ping W. Association of psoriasis with chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis. Front Med (Lausanne). 2023, 10:1175477. 10.3389\/fmed.2023.1175477","journal-title":"Front Med (Lausanne)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2024.04.015","article-title":"Chronic tonsillitis and IgA nephropathy: findings from a nationwide Japanese cohort study","volume":"84","author":"Nakayama T","year":"2024","unstructured":"Nakayama T, Kaneko H, Suzuki Y, et al.. Chronic tonsillitis and IgA nephropathy: findings from a nationwide Japanese cohort study. Am J Kidney Dis. 2024, 84:613-20.e1. 10.1053\/j.ajkd.2024.04.015","journal-title":"Am J Kidney Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000000462","article-title":"IgA nephropathy in the setting of anti-TNF-\u03b1 therapy for inflammatory bowel disease","volume":"7","author":"Strobel T","year":"2020","unstructured":"Strobel T, Ahmed W, De la Sancha C, Bohm M, Fischer M. IgA nephropathy in the setting of anti-TNF-\u03b1 therapy for inflammatory bowel disease. ACG Case Rep J. 2020, 7:e00462. 10.14309\/crj.0000000000000462","journal-title":"ACG Case Rep J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006609","article-title":"GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway","volume":"13","author":"Kiryluk K","year":"2017","unstructured":"Kiryluk K, Li Y, Moldoveanu Z, et al.. GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. PLoS Genet. 2017, 13:e1006609. 10.1371\/journal.pgen.1006609","journal-title":"PLoS Genet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad025","article-title":"Immune abnormalities in IgA nephropathy","volume":"16","author":"Gentile M","year":"2023","unstructured":"Gentile M, Sanchez-Russo L, Riella LV, et al.. Immune abnormalities in IgA nephropathy. Clin Kidney J. 2023, 16:1059-70. 10.1093\/ckj\/sfad025","journal-title":"Clin Kidney J"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.14309\/00000434-200910003-00369","article-title":"IgA nephropathy in cirrhosis; incidence, pathogenesis, and clinical significance: literature review","volume":"104","author":"Hatoum H","year":"2009","unstructured":"Hatoum H, Rzouq F. IgA nephropathy in cirrhosis; incidence, pathogenesis, and clinical significance: literature review. Am J Gastroenterol. 2009, 104:S139.","journal-title":"Am J Gastroenterol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.06.010","article-title":"Challenges in IgA nephropathy management: an era of complement inhibition","volume":"8","author":"Tesa\u0159 V","year":"2023","unstructured":"Tesa\u0159 V, Radhakrishnan J, Charu V, Barratt J. Challenges in IgA nephropathy management: an era of complement inhibition. Kidney Int Rep. 2023, 8:1730-40. 10.1016\/j.ekir.2023.06.010","journal-title":"Kidney Int Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson A","year":"2019","unstructured":"Thompson A, Carroll K, A Inker L, et al.. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019, 14:469-81. 10.2215\/CJN.08600718","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich HN","year":"2007","unstructured":"Reich HN, Troyanov S, Scholey JW, Cattran DC. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007, 18:3177-83. 10.1681\/ASN.2007050526","journal-title":"J Am Soc Nephrol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04820511","article-title":"Clinical features and outcomes of IgA nephropathy with nephrotic syndrome","volume":"7","author":"Kim JK","year":"2012","unstructured":"Kim JK, Kim JH, Lee SC, et al.. Clinical features and outcomes of IgA nephropathy with nephrotic syndrome. Clin J Am Soc Nephrol. 2012, 7:427-36. 10.2215\/CJN.04820511","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.252","article-title":"New developments in the genetics, pathogenesis, and therapy of IgA nephropathy","volume":"88","author":"Magistroni R","year":"2015","unstructured":"Magistroni R, D'Agati VD, Appel GB, Kiryluk K. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int. 2015, 88:974-89. 10.1038\/ki.2015.252","journal-title":"Kidney Int"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-024-04040-6","article-title":"Differences of clinicopathological characteristics and outcomes of IgA nephropathy patients with and without nephrotic syndrome","volume":"56","author":"Huang N","year":"2024","unstructured":"Huang N, Li J, Ai Z, Guo L, Chen W, Liu Q. Differences of clinicopathological characteristics and outcomes of IgA nephropathy patients with and without nephrotic syndrome. Int Urol Nephrol. 2024, 56:3003-11. 10.1007\/s11255-024-04040-6","journal-title":"Int Urol Nephrol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2022.2113796","article-title":"Comparison between outcomes of IgA nephropathy with nephrotic-range proteinuria and nephrotic syndrome: do podocytes play a role?","volume":"44","author":"Chen Y","year":"2022","unstructured":"Chen Y, Yang A, Hou Y, et al.. Comparison between outcomes of IgA nephropathy with nephrotic-range proteinuria and nephrotic syndrome: do podocytes play a role?. Ren Fail. 2022, 44:1443-53. 10.1080\/0886022X.2022.2113796","journal-title":"Ren Fail"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.01.024","article-title":"Comparative analysis of proteinuria and longitudinal outcomes in immune complex membranoproliferative glomerulonephritis and C3 glomerulopathy","volume":"10","author":"Caravaca-Font\u00e1n F","year":"2025","unstructured":"Caravaca-Font\u00e1n F, Toledo-Rojas R, Huerta A, et al.. Comparative analysis of proteinuria and longitudinal outcomes in immune complex membranoproliferative glomerulonephritis and C3 glomerulopathy. Kidney Int Rep. 2025, 10:1223-36. 10.1016\/j.ekir.2025.01.024","journal-title":"Kidney Int Rep"},{"key":"ref30","article-title":"Acute renal failure and tubular necrosis associated with hematuria due to glomerulonephritis","volume":"19","author":"Kincaid-Smith P","year":"1983","unstructured":"Kincaid-Smith P, Bennett WM, Dowling JP, Ryan GB. Acute renal failure and tubular necrosis associated with hematuria due to glomerulonephritis. Clin Nephrol. 1983, 19:206-10.","journal-title":"Clin Nephrol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad232","article-title":"Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients","volume":"16","author":"Zand L","year":"2023","unstructured":"Zand L, Fervenza FC, Coppo R. Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients. Clin Kidney J. 2023, 16:ii19-27. 10.1093\/ckj\/sfad232","journal-title":"Clin Kidney J"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy","volume":"179","author":"Barbour SJ","year":"2019","unstructured":"Barbour SJ, Coppo R, Zhang H, et al.. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019, 179:942-52. 10.1001\/jamainternmed.2019.0600","journal-title":"JAMA Intern Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000242","article-title":"Treatment of IgA nephropathy: a rapidly evolving field","volume":"35","author":"El Karoui K","year":"2024","unstructured":"El Karoui K, Fervenza FC, De Vriese AS. Treatment of IgA nephropathy: a rapidly evolving field. J Am Soc Nephrol. 2024, 35:103-16. 10.1681\/ASN.0000000000000242","journal-title":"J Am Soc Nephrol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.11.008","article-title":"Persistent hematuria and kidney disease progression in IgA nephropathy: a cohort study","volume":"76","author":"Yu GZ","year":"2020","unstructured":"Yu GZ, Guo L, Dong JF, et al.. Persistent hematuria and kidney disease progression in IgA nephropathy: a cohort study. Am J Kidney Dis. 2020, 76:90-9. 10.1053\/j.ajkd.2019.11.008","journal-title":"Am J Kidney Dis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-013-0849-x","article-title":"Proposal of remission criteria for IgA nephropathy","volume":"18","author":"Suzuki Y","year":"2014","unstructured":"Suzuki Y, Matsuzaki K, Suzuki H, et al.. Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol. 2014, 18:481-6. 10.1007\/s10157-013-0849-x","journal-title":"Clin Exp Nephrol"},{"key":"ref36","doi-asserted-by":"crossref","DOI":"10.1093\/oxfordjournals.ndt.a092430","article-title":"Acute reversible renal failure with macroscopic haematuria in IgA nephropathy","volume":"8","author":"Delclaux C","year":"1993","unstructured":"Delclaux C, Jacquot C, Callard P, Kleinknecht D. Acute reversible renal failure with macroscopic haematuria in IgA nephropathy. Nephrol Dial Transplant. 1993, 8:195-9.","journal-title":"Nephrol Dial Transplant"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.09.017","article-title":"One-year estimated GFR slope independently predicts clinical benefit in immunoglobulin A nephropathy","volume":"7","author":"Lafayette RA","year":"2022","unstructured":"Lafayette RA, Reich HN, Stone AM, Barratt J. One-year estimated GFR slope independently predicts clinical benefit in immunoglobulin A nephropathy. Kidney Int Rep. 2022, 7:2730-3. 10.1016\/j.ekir.2022.09.017","journal-title":"Kidney Int Rep"},{"key":"ref38","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy","volume":"24","author":"Manno C","year":"2009","unstructured":"Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009, 24:3694-701.","journal-title":"Nephrol Dial Transplant"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv J","year":"2022","unstructured":"Lv J, Wong MG, Hladunewich MA, et al.. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022, 327:1888-98. 10.1001\/jama.2022.5368","journal-title":"JAMA"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen T","year":"2020","unstructured":"Rauen T, Eitner F, Fitzner C, et al.. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020, 98:1044-52. 10.1016\/j.kint.2020.04.046","journal-title":"Kidney Int"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin BH","year":"2023","unstructured":"Rovin BH, Barratt J, Heerspink HJL, et al.. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023, 402:2077-90. 10.1016\/S0140-6736(23)02302-4","journal-title":"Lancet"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref43","article-title":"Targeted-release budesonide (nefecon) in patients with IgA nephropathy (NefIgArd): a phase 3 trial","volume":"103","author":"Fellstr\u00f6m BC","year":"2023","unstructured":"Fellstr\u00f6m BC, Barratt J, Cook HT, et al.. Targeted-release budesonide (nefecon) in patients with IgA nephropathy (NefIgArd): a phase 3 trial. Kidney Int. 2023, 103:1356-67.","journal-title":"Kidney Int"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher D","year":"2023","unstructured":"Pitcher D, Braddon F, Hendry B, et al.. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023, 18:727-38. 10.2215\/CJN.0000000000000135","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattran DC","year":"2009","unstructured":"Cattran DC, Coppo R, Cook HT, et al.. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009, 76:534-45. 10.1038\/ki.2009.243","journal-title":"Kidney Int"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016040433","article-title":"A multicenter study of the predictive value of crescents in IgA nephropathy","volume":"28","author":"Haas M","year":"2017","unstructured":"Haas M, Verhave JC, Liu ZH, et al.. A multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol. 2017, 28:691-701. 10.1681\/ASN.2016040433","journal-title":"J Am Soc Nephrol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group","volume":"91","author":"Trimarchi H","year":"2017","unstructured":"Trimarchi H, Barratt J, Cattran DC, et al.. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int. 2017, 91:1014-21. 10.1016\/j.kint.2017.02.003","journal-title":"Kidney Int"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01470506","article-title":"Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Sch\u00f6nlein-Henoch purpura nephritis","volume":"2","author":"Hara M","year":"2007","unstructured":"Hara M, Yanagihara T, Kihara I. Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Sch\u00f6nlein-Henoch purpura nephritis. Clin J Am Soc Nephrol. 2007, 2:231-8. 10.2215\/CJN.01470506","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/4.11.943","article-title":"Frequency of mesangial IgA deposits in a non-selected autopsy series","volume":"4","author":"Waldherr R","year":"1989","unstructured":"Waldherr R, Rambausek M, Duncker WD, Ritz E. Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant. 1989, 4:943-6. 10.1093\/ndt\/4.11.943","journal-title":"Nephrol Dial Transplant"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(89)80168-4","article-title":"Mesangial IgA nephropathy with steroid-responsive nephrotic syndrome: disappearance of mesangial IgA deposits following steroid-induced remission","volume":"14","author":"Cheng IK","year":"1989","unstructured":"Cheng IK, Chan KW, Chan MK. Mesangial IgA nephropathy with steroid-responsive nephrotic syndrome: disappearance of mesangial IgA deposits following steroid-induced remission. Am J Kidney Dis. 1989, 14:361-4. 10.1016\/s0272-6386(89)80168-4","journal-title":"Am J Kidney Dis"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.5414\/CN107682","article-title":"Clinicopathologic features and treatment response in nephrotic IgA nephropathy with minimal change disease","volume":"79","author":"Qin J","year":"2013","unstructured":"Qin J, Yang Q, Tang X, et al.. Clinicopathologic features and treatment response in nephrotic IgA nephropathy with minimal change disease. Clin Nephrol. 2013, 79:37-44. 10.5414\/CN107682","journal-title":"Clin Nephrol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00464.2007","article-title":"Activation of podocytes by mesangial-derived TNF-\u03b1: glomerulo-podocytic communication in IgA nephropathy","volume":"294","author":"Lai KN","year":"2008","unstructured":"Lai KN, Leung JC, Chan LY, et al.. Activation of podocytes by mesangial-derived TNF-\u03b1: glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol. 2008, 294:F945-55. 10.1152\/ajprenal.00464.2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments","volume":"86","author":"Coppo R","year":"2014","unstructured":"Coppo R, Troyanov S, Bellur S, et al.. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014, 86:828-36. 10.1038\/ki.2014.63","journal-title":"Kidney Int"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.460","article-title":"Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies","volume":"79","author":"El Karoui K","year":"2011","unstructured":"El Karoui K, Hill GS, Karras A, et al.. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies. Kidney Int. 2011, 79:643-54. 10.1038\/ki.2010.460","journal-title":"Kidney Int"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.03.017","article-title":"Arteriolar C4D in IgA nephropathy: a cohort study","volume":"76","author":"Faria B","year":"2020","unstructured":"Faria B, Can\u00e3o P, Cai Q, et al.. Arteriolar C4D in IgA nephropathy: a cohort study. Am J Kidney Dis. 2020, 76:669-78. 10.1053\/j.ajkd.2020.03.017","journal-title":"Am J Kidney Dis"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.08.011","article-title":"Urinary soluble CD163: a novel biomarker suggests who should receive glucocorticoids in IgA nephropathy","volume":"9","author":"Li G","year":"2024","unstructured":"Li G, Thanabalasingam SJ. Urinary soluble CD163: a novel biomarker suggests who should receive glucocorticoids in IgA nephropathy. Kidney Int Rep. 2024, 9:2848-50. 10.1016\/j.ekir.2024.08.011","journal-title":"Kidney Int Rep"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010111130","article-title":"A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy","volume":"23","author":"El Karoui K","year":"2012","unstructured":"El Karoui K, Hill GS, Karras A, et al.. A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J Am Soc Nephrol. 2012, 23:137-48. 10.1681\/ASN.2010111130","journal-title":"J Am Soc Nephrol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.466","article-title":"Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. I. Immunohistochemical studies","volume":"79","author":"Hill GS","year":"2011","unstructured":"Hill GS, Karoui KE, Karras A, Mandet C, Van Huyen JD, Nochy D, Bruneval P. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. I. Immunohistochemical studies. Kidney Int. 2011, 79:635-42. 10.1038\/ki.2010.466","journal-title":"Kidney Int"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00619-4","article-title":"Blood and urine biomarkers of disease progression in IgA nephropathy","volume":"12","author":"Duan ZY","year":"2024","unstructured":"Duan ZY, Zhang C, Chen XM, Cai GY. Blood and urine biomarkers of disease progression in IgA nephropathy. Biomark Res. 2024, 12:72. 10.1186\/s40364-024-00619-4","journal-title":"Biomark Res"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13477","article-title":"High levels of urinary complement proteins are associated with chronic renal damage and proximal tubule dysfunction in immunoglobulin A nephropathy","volume":"24","author":"Wen L","year":"2019","unstructured":"Wen L, Zhao Z, Wang Z, Xiao J, Birn H, Gregersen JW. High levels of urinary complement proteins are associated with chronic renal damage and proximal tubule dysfunction in immunoglobulin A nephropathy. Nephrology (Carlton). 2019, 24:703-10. 10.1111\/nep.13477","journal-title":"Nephrology (Carlton)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/419643-the-immunoglobulin-a-nephropathy-renaissance-from-pathogenesis-to-personalized-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:28:45Z","timestamp":1764325725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/419643-the-immunoglobulin-a-nephropathy-renaissance-from-pathogenesis-to-personalized-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":60,"URL":"https:\/\/doi.org\/10.7759\/cureus.97999","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,28]]}}}